Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT02586207 2025-10-07

Pembrolizumab in Combination With CRT for LA-SCCHN

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03641547 2024-07-18

CHARIOT

Phase 1 Completed

36 enrolled 24 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT02308072 2024-05-08

ORCA-2

Phase 1 Active not recruiting

70 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02158234 2023-01-19

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

Phase 1 Completed

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Diseases

NCT01445405 2019-12-17

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

Phase 1 Completed

3 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Pharyngeal Neoplasms

NCT02035527 2018-05-24

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Completed

3 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00450138 2016-08-29

Open Label, Phase I ZD6474 Head and Neck Cancer Study

Phase 1 Completed

48 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00627835 2016-07-20

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Phase 1 Withdrawn

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00935961 2013-08-09

RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Phase 1 Completed

18 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00185835 2010-03-29

Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck

Phase 1 Completed

10 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Clinical Trials

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Pembrolizumab in Combination With CRT for LA-SCCHN

CHARIOT

ORCA-2

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Open Label, Phase I ZD6474 Head and Neck Cancer Study

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck